Coherus BioSciences, Inc. (NASDAQ:CHRS) Shares Acquired by Pictet Asset Management SA

Pictet Asset Management SA boosted its holdings in Coherus BioSciences, Inc. (NASDAQ:CHRSGet Rating) by 35.4% during the 2nd quarter, HoldingsChannel reports. The institutional investor owned 167,828 shares of the biotechnology company’s stock after purchasing an additional 43,889 shares during the quarter. Pictet Asset Management SA’s holdings in Coherus BioSciences were worth $1,215,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the business. Texas Permanent School Fund raised its holdings in Coherus BioSciences by 2.1% in the second quarter. Texas Permanent School Fund now owns 46,115 shares of the biotechnology company’s stock valued at $334,000 after buying an additional 932 shares during the period. CM Management LLC raised its holdings in Coherus BioSciences by 33.3% in the second quarter. CM Management LLC now owns 200,000 shares of the biotechnology company’s stock valued at $1,448,000 after buying an additional 50,000 shares during the period. FDx Advisors Inc. raised its holdings in Coherus BioSciences by 14.6% in the second quarter. FDx Advisors Inc. now owns 13,612 shares of the biotechnology company’s stock valued at $99,000 after buying an additional 1,738 shares during the period. Comerica Bank raised its holdings in Coherus BioSciences by 2.1% in the second quarter. Comerica Bank now owns 54,580 shares of the biotechnology company’s stock valued at $416,000 after buying an additional 1,125 shares during the period. Finally, SG Americas Securities LLC raised its holdings in Coherus BioSciences by 61.9% in the second quarter. SG Americas Securities LLC now owns 71,068 shares of the biotechnology company’s stock valued at $515,000 after buying an additional 27,173 shares during the period. Hedge funds and other institutional investors own 97.67% of the company’s stock.

Coherus BioSciences Stock Down 0.8 %

CHRS stock opened at $6.55 on Wednesday. Coherus BioSciences, Inc. has a twelve month low of $5.60 and a twelve month high of $19.00. The company has a current ratio of 2.62, a quick ratio of 2.45 and a debt-to-equity ratio of 33.47. The company has a market capitalization of $509.45 million, a P/E ratio of -1.82 and a beta of 1.03. The firm has a 50 day simple moving average of $8.60 and a 200-day simple moving average of $8.85.

Wall Street Analyst Weigh In

Several research analysts recently commented on CHRS shares. JPMorgan Chase & Co. cut their price target on shares of Coherus BioSciences from $13.00 to $11.00 and set a “neutral” rating on the stock in a report on Monday, November 14th. Mizuho dropped their price objective on shares of Coherus BioSciences from $28.00 to $21.00 and set a “buy” rating on the stock in a research note on Wednesday, November 16th. StockNews.com began coverage on shares of Coherus BioSciences in a research note on Wednesday, October 12th. They set a “hold” rating on the stock. Finally, Maxim Group dropped their price objective on shares of Coherus BioSciences to $15.00 in a research note on Thursday, November 17th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $16.50.

Coherus BioSciences Profile

(Get Rating)

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis.

See Also

Want to see what other hedge funds are holding CHRS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Coherus BioSciences, Inc. (NASDAQ:CHRSGet Rating).

Institutional Ownership by Quarter for Coherus BioSciences (NASDAQ:CHRS)

Receive News & Ratings for Coherus BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.